Anuja Java to Lead Pilot Core in National TMA Consortium: The IMPACT Study

WashU Nephrology is proud to announce that transplant nephrologist Anuja Java, MD, has received a Clinical and Translational Science Award (U54) for her role in the newly funded Thrombotic Microangiopathies Consortium of the Rare Disease Clinical Research Network(RDCRN).  

The initiative, known as the IMPACT Study (Initiation of a cohort to define pathogenic Mechanisms, Precision diagnosis And Complications of Thrombotic Microangiopathies), aims to advance precision diagnosis and treatment of rare thrombotic microangiopathies (TMAs).  Funded under U54 HL185004-01, the grant is supported by the National Institutes of Health (NIH) and the National Center for Advancing Translational Sciences (NCATS).

The consortium brings together experts from Johns Hopkins, Ohio State, Washington University, and other leading institutions.  It supports multi-center collaboration, patient registries, and precision medicine approaches to improve outcomes for individuals affected by TMAs, rare but serious conditions involving blood clotting in small vessels, often leading to organ damage. 

Dr. Java, who serves as Director of Kidney Transplant at John Cochran VA Medical Center, will lead the pilot core of the study.  Her research focuses on complement-mediated diseases such as atypical hemolytic uremic syndrome (aHUS), which are central to the study.  She is widely recognized for her work on genetic variants in complement pathways, helping guide individualized treatment decisions for patients with TMAs. 

The IMPACT Study will build a longitudinal cohort to better understand disease mechanisms, refine diagnostic precision, and explore individualized treatment strategies.

---

Follow @anuja_java on X.